Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia

Endocrinology

Volumn 151, Issue 8, 2010, Pages 3975-3984

  Zenzmaier, Christoph ^a   Sampson, Natalie ^a   Pernkopf, Dominik ^b   Plas, Eugen ^b   Untergasser, Gerold ^c   Berger, Peter ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIC GMP; MITOGEN ACTIVATED PROTEIN KINASE 1; NITRIC OXIDE; PHOSPHODIESTERASE V; SMALL INTERFERING RNA; TADALAFIL; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; MYOFIBROBLAST; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; RNA INTERFERENCE; STROMA CELL;

CARBOLINES; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PROSTATE; PROSTATIC HYPERPLASIA; RNA, SMALL INTERFERING; STROMAL CELLS; TREATMENT OUTCOME;

EID: 77954940478     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1411     Document Type: Article

References (40)

1. Rosen RC, Kostis JB 2003 Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 92:9M-18M
2. Guazzi M, Arena R, Pinkstaff S, Guazzi MD 2009 Six months of sildenafil therapy improves heart rate recovery in patients with heart failure. Int J Cardiol 136:341-343
3. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M 2004 Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145:2253-2263
4. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus S, Liebert M, Moul JW, Tangen C, Thrasher JB, Thompson I 2007 Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 178:597-601
5. Sampson N, Untergasser G, Plas E, Berger P 2007 The ageing male reproductive tract. J Pathol 211:206-218
6. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ 2004 EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46:547-554 (Pubitemid 39345720)
7. Roehrborn CG 2008 BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101(Suppl 3):17-21
8. Bartsch G, Frick J, Rüegg I, Bucher M, Holliger O, Oberholzer M, Rohr HP 1979 Electron microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122:481-486 (Pubitemid 10245529)
9. Bartsch G, Müller HR, Oberholzer M, Rohr HP 1979 Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122:487-491 (Pubitemid 10245530)
10. Mullan RJ, Bergstralh EJ, Farmer SA, Jacobson DJ, Hebbring SJ, Cunningham JM, Thibodeau SN, Lieber MM, Jacobsen SJ, Roberts RO 2006 Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men. Urology 67:300-305
11. Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C, Sato K, Kamoto T, Ogawa O, Kato T 2004 Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-β1 gene polymorphism at codon10. Carcinogenesis 25:237-240
12. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR 2002 Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8:2912-2923
13. Untergasser G, Gander R, Lilg C, Lepperdinger G, Plas E, Berger P 2005 Profiling molecular targets of TGF-β1 in prostate fibroblast-to- myofibroblast transdifferentiation. Mech Ageing Dev 126:59-69 (Pubitemid 40018478)
14. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS 1986 Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167-4171
15. Kohler TS, McVary KT 2009 The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 55:38-48
16. Roumeguère T, Zouaoui Boudjeltia K, Hauzeur C, Schulman C, Vanhaeverbeek M, Wespes E 2009 Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU Int 104: 511-517
17. Uckert S, Sormes M, Kedia G, Scheller F, Knapp WH, Jonas U, Stief CG 2008 Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 71:526-530 (Pubitemid 351374723)
18. Grimsley SJ, Khan MH, Jones GE 2007 Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 69:25-26
19. Kang KK, Kim JM, Yu JY, Ahn BO, Yoo M, Kim YC 2007 Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia. Int J Urol 14:946-951; discussion 951
20. Tinel H, Stelte-Ludwig B, Hütter J, Sandner P 2006 Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 98:1259-1263 (Pubitemid 44721238)
21. Cook AL, Haynes JM 2004 Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 16:253-261
22. Zenzmaier C, Untergasser G, Hermann M, Dirnhofer S, Sampson N, Berger P 2008 Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue. Prostate 68:540-547 (Pubitemid 351500214)
23. Briganti A, Salonia A, Gallina A, Saccà A, Montorsi P, Rigatti P, Montorsi F 2005 Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nat Clin Pract Urol 2:239-247 (Pubitemid 40823126)
24. Loughney K, Taylor J, Florio VA 2005 3′,5′-cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res 17:320-325 (Pubitemid 41025763)
25. Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P 2006 Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49:740-745 (Pubitemid 43374744)
26. Oliveira CJ, Schindler F, Ventura AM, Morais MS, Arai RJ, Debbas V, Stern A, Monteiro HP 2003 Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radic Biol Med 35: 381-396 (Pubitemid 37289168)
27. Peehl DM, Sellers RG 1997 Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res 232: 208-215
28. Rumpold H, Mascher K, Untergasser G, Plas E, Hermann M, Berger P 2002 Trans-differentiation of prostatic stromal cells leads to decreased glycoprotein hormone α production. J Clin Endocrinol Metab 87:5297-5303 (Pubitemid 35316377)
29. Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O, Sale P, Berardi A, Petrangeli E, Gallucci M, Di Silverio F, Russo MA 1999 Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 189:224-229
30. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, Marini M, Gacci M, Vannelli GB, Sandner P, Maggi M 2010 Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 7:59-69
31. Foresta C, Caretta N, Zuccarello D, Poletti A, Biagioli A, Caretti L, Galan A 2008 Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. Eye 22: 144-149
32. Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR 2005 Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172:105-113
33. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A 2007 Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 572:12-22 (Pubitemid 47374681)
34. Osinski MT, Rauch BH, Schrör K 2001 Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol 59:1044-1050 (Pubitemid 32381583)
35. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, Branzi A, Galié N 2005 Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100: 131-138
36. Koyama H, Bornfeldt KE, Fukumoto S, Nishizawa Y 2001 Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 186:1-10
37. Li B, Yang L, Shen J, Wang C, Jiang Z 2007 The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. Anesth Analg 105:1034-1041
38. Chambers RC, Leoni P, Kaminski N, Laurent GJ, Heller RA 2003 Global expression profiling of fibroblast responses to transforming growth factor-β1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 162:533-546
39. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G 1993 Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122:103-111
40. Vernet D, Magee T, Qian A, Nolazco G, Rajfer J, Gonzalez-Cadavid N 2006 Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med 3:84-94; discussion 94-85